Companies / BOC Sciences / Lumiliximab
BOC Sciences

Lumiliximab | BOC Sciences

Lumiliximab is a chimeric monoclonal antibody that targets CD23. Lumiliximab is undergoing clinical trials for the treatment of chronic lymphocytic leukaemia.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.